Academic Journal
Q2Pharmacoepidemiology
About Pharmacoepidemiology
Pharmacoepidemiology is a scholarly journal published by Multidisciplinary Digital Publishing Institute (MDPI). SCImago 2025 lists it in Q2, with an SJR of 0.354 and H-index of 6.
Coverage: 2022-2025. Research categories: Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q2); Pharmacology (medical) (Q3); Public Health, Environmental and Occupational Health (Q3); Genetics (Q4).
Verified field sources
- Journal Impact Factor: 1.6 — Official source; checked 2026-10-03. Journal Impact Factor and reporting year from the publisher imprint.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal Impact Factor and reporting year from the publisher imprint.
- Contact email: pharmacoepidemiology@mdpi.com — Official source; checked 2026-10-03. Journal editorial office email published by MDPI; manuscript files use the submission system.
- Editor(s): Dr. Carlotta Franchi (Editor-in-Chief) — Official source; checked 2026-10-03. Current chief editor(s) listed on the official MDPI editorial board. Founding and section editors excluded.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2023-03-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Pharmacovigilance and Adverse Drug Reactions; Statistical Methods in Clinical Trials; Pharmaceutical Practices and Patient Outcomes; Health Systems, Economic Evaluations, Quality of Life; Pharmaceutical studies and practices; Pharmaceutical Economics and Policy.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Real-World Utilization, Safety, and Early Clinical Reassessment of Antihypertensive Therapy in Primary Care
Njomza Lajçi Berisha, Arieta Hasani Alidema, Fitim Alidema
2026-10-01 · DOI: 10.3390/pharma5040039Evaluation of Systemic Pharmacotherapy in Bacterial Skin Infections: Adherence to Clinical Guidelines and Factors Associated with Treatment Outcomes
Lirim Shefki Mustafa, Arieta Hasani Alidema, Mirlinda Havolli, Linda Connelly et al.
2026-09-22 · DOI: 10.3390/pharma5040038Perceived Credibility and Information-Verification Behavior in Relation to Self-Medication Influenced by Health Information on Social Media: A Cross-Sectional Study
Úrsula Ghassan El Awar, Lara Ghassan El Awar, Pietro Chaves Amaral Miralha, Francisco Jordano da Silva Feitosa et al.
2026-09-20 · DOI: 10.3390/pharma5030037The Burden of Disease of Medication Errors: Analysis in ADR Caused Emergency Visits
Justyna Wozniak, Katja S. Just, Catharina Scholl, Andrea Kriegisch-Stumpf et al.
2026-09-19 · DOI: 10.3390/pharma5030036Clinical and Medication-Related Factors Associated with Adverse Renal Outcomes in Advanced Chronic Kidney Disease Patients Treated with Empagliflozin: A Real-World Study in Thailand
Ittaprach Yimsuk, Artitaya Vongsaroj, Pikanet Suebchompoo, Adisorn Attarungrod et al.
2026-09-17 · DOI: 10.3390/pharma5030035Shifts Toward Direct Oral Anticoagulants in Ambulatory Care: Utilization Trends and SARIMA Forecasts
Vasiliki Gougoula, Konstantinos Kassandros, Panagiotis Nikolaos Lalagkas, Evangelia Nena et al.
2026-09-08 · DOI: 10.3390/pharma5030034Primary Non-Adherence to Electronic Prescriptions in Lithuania, 2018–2024: Nationwide Prevalence, Factors, and Regional Variation
Viktorija Butrimaite, Marija Blockyte, Jurga Andreja Kazlauskaite, Tomas Lasys et al.
2026-09-07 · DOI: 10.3390/pharma5030033Exploring the Medical Prescription of Cannabis sp.-Derived Products in Brazil: A National Cross-Sectional Survey
Caroline Taira Takara, Beatriz Inacio Gonçalves, Taynna Tatiane Pereira, Tácio de Mendonça Lima et al.
2026-08-31 · DOI: 10.3390/pharma5030032Serum Prolactin and Bone Mineral Density in Women with Schizophrenia Receiving Prolactin-Raising Antipsychotics: A Cross-Sectional Study
Kamonrat Somrak, Chompoonuch Werawattanachai, Apiradee Sangngarm, Sipanut Silaket et al.
2026-08-26 · DOI: 10.3390/pharma5030031Report-Level Comparator-Definition Sensitivity in FAERS Cardiometabolic Disproportionality Analysis: A Long-Acting Cabotegravir/Rilpivirine HIV Pharmacovigilance Case Study
Shigeru Hasebe, Chihiro Nishikawa, Yuki Miura, Taiki Kusaka et al.
2026-08-20 · DOI: 10.3390/pharma5030030Virologic Outcomes of Predominantly Tenofovir-Based First-Line Antiretroviral Therapy Among Treatment-Naïve HIV Patients in Davao City, Philippines
Alfredo A. Hinay, Avee Joy B. Dayaganon, Aprilyn F. Francisco-Breva, Jennifer Ashley H. Reyes et al.
2026-08-12 · DOI: 10.3390/pharma5030029An Overview of Antibiotic Consumption in Croatian Counties, 2017–2024: Temporal and Geographic Patterns Before, During, and After the COVID-19 Pandemic
Sanda Tešanović, Ljiljana Betica Radić, Ankica Džono Boban, Pero Draganić et al.
2026-08-07 · DOI: 10.3390/pharma5030028Reported Private-Sector Dispensing Trends of Methylphenidate in Costa Rica, 2017–2024: An Ecological Drug-Utilization Study
Esteban Zavaleta-Monestel, Luis Guillermo Herrera-Jiménez, Jeaustin Mora-Jiménez, Sebastián Arguedas-Chacón et al.
2026-07-28 · DOI: 10.3390/pharma5030027Influenza Vaccine Effectiveness Among Italian Adults: A Test-Negative Case–Control Study from an Italian Southern Province During the 2024/25 Winter Season
Giuseppe Di Martino, Giustino Parruti, Graziella Soldato, Fabrizio Cedrone et al.
2026-07-24 · DOI: 10.3390/pharma5030026Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026)
Stanislav Kotlyarov, Anna Kotlyarova
2026-07-23 · DOI: 10.3390/pharma5030025Comparison of Two Triple Therapy Regimens for Helicobacter pylori Eradication in Patients with Dyspepsia: A Retrospective Study from Primary Care
Lirim Shefki Mustafa, Fitim Bexhet Alidema
2026-07-13 · DOI: 10.3390/pharma5030024Use of the Zipf–Mandelbrot Law in Modelling US FDA Adverse Reactions
Glen Atlas, Sunil Dhar, George Tewfik, Dhvani Shihora et al.
2026-07-06 · DOI: 10.3390/pharma5030023Assessment of Inappropriate Omeprazole Prescribing, Associated Factors and Financial Impact in the Outpatient Department of a General Hospital in Thailand
Saranporn Srithonrat, Chayanat Pongsathabordee, Satawat Kulworahathai, Chidawan Prapat et al.
2026-07-02 · DOI: 10.3390/pharma5030022Signal Characterization of Insulin Glargine Product Groups in the United States Food and Drug Administration Adverse Event Reporting System
Elaf M. Basheer, Mohammed Ibrahim Aladul
2026-06-30 · DOI: 10.3390/pharma5030021Medication Adherence and Its Discordance with Glycemic Control in Type 2 Diabetes: A Real-World Study in Primary Health Care in the Brazilian Amazon
Laila de Castro Araújo, Valéria dos Santos Lourenço, Valéria de Castro Fagundes, Alana Ferreira de Oliveira et al.
2026-06-26 · DOI: 10.3390/pharma5030020Reviews
Community Reviews
Version History
October 2, 2026 at 9:49 pm
October 2, 2026